---
schema_version: "secwatch.filing_event.v1"
accession: "0001722482-21-000194"
form_type: "8-K"
ticker: "AVTR"
cik: "0001722482"
company_name: "Avantor, Inc."
filed_at: "2021-07-19T23:59:59+00:00"
generated_at: "2026-06-30T04:31:40.561838+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.18
calibrated_materiality_score: 0.18
confidence: "high"
source: SEC EDGAR
---

# Avantor appoints John Carethers, M.D. as independent Class III director

## Summary
- John Carethers, M.D., age 57, appointed to serve as Class III director with term expiring at 2022 annual meeting.
- Carethers is Chair, Department of Internal Medicine at University of Michigan Medical School; member of National Academy of Medicine.
- Standard non-employee director compensation: prorated $75,000 annual cash retainer and prorated $200,000 RSU grant.
- RSUs vest one year from grant date, subject to continued service; board has determined independence under NYSE standards.

## SEC filing metadata
- accession: 0001722482-21-000194
- form_type: 8-K
- ticker: AVTR
- cik: 0001722482
- company_name: Avantor, Inc.
- filed_at: 2021-07-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.18
- calibrated_materiality_score: 0.18
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1722482/000172248221000194/0001722482-21-000194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1722482/000172248221000194/avtr-20210715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001722482-21-000194
- JSON: https://secwatch.observer/filing/0001722482-21-000194.json
- Plain text: https://secwatch.observer/filing/0001722482-21-000194.txt

## Key facts
- Executive change
  John Carethers, M.D. was appointed as Director at Avantor, Inc..
  - Action: appointed
  - Role: Director
  source text: On July 15, 2021, the Board, upon the recommendation of its Nominating and Governance Committee, appointed John Carethers, M.D. as a Class III director with an initial term expiring at the Company’s 2022 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1722482/000172248221000194/0001722482-21-000194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.